Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Artelo Biosciences, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 8 | 9 | +1 |
| Shares | 86.6K | 16.6K | −70.0K (−80.8%) |
| Value | $75.8K | $220.1K | +$144.4K (+190.5%) |
New holders (4)
Institutions that held Artelo Biosciences, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 9 | $119 | 0.00% |
| FMR LLC | 1 | $13 | 0.00% |
| Danske Bank A/S | 1 | $13 | 0.00% |
| Royal Bank of Canada | 1 | $0 | 0.00% |
Sold out (3)
Institutions that held Artelo Biosciences, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Citadel Advisors LLC | 22,706 | $19.9K |
| Susquehanna International Group, LLP | 20,388 | $17.8K |
| Rothschild Investment LLC | 8 | $7 |